AR062674A1 - Formulacion acuosa que comprende un agente antitumoral - Google Patents

Formulacion acuosa que comprende un agente antitumoral

Info

Publication number
AR062674A1
AR062674A1 ARP070103931A ARP070103931A AR062674A1 AR 062674 A1 AR062674 A1 AR 062674A1 AR P070103931 A ARP070103931 A AR P070103931A AR P070103931 A ARP070103931 A AR P070103931A AR 062674 A1 AR062674 A1 AR 062674A1
Authority
AR
Argentina
Prior art keywords
antitumoral agent
watery
understanding
quinolyloxy
phenoxy
Prior art date
Application number
ARP070103931A
Other languages
English (en)
Inventor
William I Rocco
Jiping Liu
Olivier Dorchies
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR062674A1 publication Critical patent/AR062674A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones y formulaciones farmacéuticas que comprenden ácido (2R)-2-[4-(7-bromo-2-quinoliloxi)fenoxi]propanoico, y métodos de uso de las mismas. Reivindicacion 1: Una formulacion acuosa farmacéuticamente aceptable que comprende ácido (2R)-2-[4- (7-bromo-2-quinoliloxi)fenoxi]propanoico o una sal del mismo farmacéuticamente aceptable, un ciclodextrina fisiologicamente aceptable, y al menos un agente potenciador de la solubilidad.
ARP070103931A 2006-09-07 2007-09-06 Formulacion acuosa que comprende un agente antitumoral AR062674A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291410A EP1897542A1 (en) 2006-09-07 2006-09-07 Aqueous formulation comprising an antitumor agent

Publications (1)

Publication Number Publication Date
AR062674A1 true AR062674A1 (es) 2008-11-26

Family

ID=37728353

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103931A AR062674A1 (es) 2006-09-07 2007-09-06 Formulacion acuosa que comprende un agente antitumoral

Country Status (16)

Country Link
EP (2) EP1897542A1 (es)
JP (1) JP2010502691A (es)
KR (1) KR20090050070A (es)
CN (1) CN101511362A (es)
AR (1) AR062674A1 (es)
AU (1) AU2007293174A1 (es)
BR (1) BRPI0717034A2 (es)
CA (1) CA2660685A1 (es)
CL (1) CL2007002598A1 (es)
IL (1) IL197072A0 (es)
MX (1) MX2009002280A (es)
PE (1) PE20081366A1 (es)
RU (1) RU2009112624A (es)
TW (1) TW200817005A (es)
UY (1) UY30579A1 (es)
WO (1) WO2008029282A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2012175434A1 (en) 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2456173A1 (en) * 2001-07-31 2003-02-13 Wayne State University Quinoline derivatives and use thereof as antitumor agents
UA79293C2 (en) * 2002-07-03 2007-06-11 Univ Wayne State 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents

Also Published As

Publication number Publication date
CL2007002598A1 (es) 2008-04-18
JP2010502691A (ja) 2010-01-28
PE20081366A1 (es) 2008-11-28
RU2009112624A (ru) 2010-10-20
MX2009002280A (es) 2009-03-13
CA2660685A1 (en) 2008-03-13
AU2007293174A1 (en) 2008-03-13
UY30579A1 (es) 2008-03-31
EP1897542A1 (en) 2008-03-12
EP2068876A2 (en) 2009-06-17
WO2008029282A2 (en) 2008-03-13
IL197072A0 (en) 2009-11-18
CN101511362A (zh) 2009-08-19
TW200817005A (en) 2008-04-16
BRPI0717034A2 (pt) 2014-05-20
WO2008029282A3 (en) 2008-05-22
KR20090050070A (ko) 2009-05-19

Similar Documents

Publication Publication Date Title
ES2244831T5 (es) Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica
CY1121782T1 (el) Διαδικασια για ξηρανση της bibw2992, tων αλατων αυτης και στερεων φαρμακευτικων σκευασματων που περιλαμβανουν αυτο το δραστικο συστατικο
UA100966C2 (ru) Фармацевтическая композиция на основе 2-[4-(4-хлорбензоил)фенокси]-2-метилпропионовой кислоты и ее солей
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
CY1115386T1 (el) Συνδυασμος αζελαστινης και μομεταζονης
ECSP045496A (es) "preparaciones acidas de insulina con estabilidad mejorada"
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2007056205A3 (en) Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
AR055838A1 (es) Formulaciones para microproyecciones recubiertas que tienen solubilidad controlada
AR055363A1 (es) Formulaciones farmaceuticas que comprenden un beta 2- agonista de accion prolongada para administracion por nebulizacion
AR057422A1 (es) Uan composicion farmaceutica de liberacion modificada, proceso de preparacion de dicha composicion y metodo para emplear la misma
CR8220A (es) Composicion de fexofenadina y proceso para su preparacion
HK1123193A1 (en) Argatroban formulation comprising an acid as solubilizer
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
CO6491061A2 (es) Formulacion de omeprazol farmaceutica estable para administracion oral
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
AR062674A1 (es) Formulacion acuosa que comprende un agente antitumoral
AR059838A1 (es) Formulaciones para dosis estabilizantes de estatina
EA201270745A1 (ru) Улучшенный стабильный водный состав (e)-4-карбоксистирил-4-хлорбензилсульфона
ECSP044979A (es) Uso de bibn4096 en combinación con otros fármacos antimigrañosos para el tratamiento de migraña
AR043418A1 (es) Formulaciones liquidas de las proteinas de union del factor necrosis del tumor
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
UY38055A (es) Composiciones oftálmicas de compuestos de bencimidazol para uso unico diario
AU2002333536A1 (en) Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure